INmune Bio, Inc. (INMB) Financials

INMB Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 26.8 million 6.5 million
March 31, 2026 25.8 million 6.2 million
Dec. 31, 2025 32.4 million 8.8 million
Sept. 30, 2025 33.4 million 8.0 million

INMB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -3.6 million 1.4 million
March 31, 2026 -3.4 million 1.5 million
Dec. 31, 2025 -3.7 million -6.6 million
Sept. 30, 2025 -5.6 million 3.0 million

INMB Net Income

No data available :(

INMB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 18.4 million - 1.4 million
March 31, 2026 21.4 million - 1.5 million
Dec. 31, 2025 24.8 million - 1.0 million
Sept. 30, 2025 27.7 million - 1.1 million

INMB Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 26.7 million
March 31, 2026 26.6 million
Dec. 31, 2025 26.6 million
Sept. 30, 2025 26.6 million

INMB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 430000 803000 2.3 million -
March 31, 2026 - 3.6 million 2.2 million -
Dec. 31, 2025 705999 2.3 million 3.1 million -
Sept. 30, 2025 193000 4.9 million 2.7 million 134000

INMB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 52000
Dec. 31, 2025 - 56000
Sept. 30, 2025 - 28000

INMB

Price: $2.11

52 week price:
1.09
2.85

Earnings Per Share: -0.60 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 49961

Market Capitalization: 56.6 million

Links: